Article
Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer.
Cancer research - 1 Oct 2020
Hanrahan Aphrothiti J, Sylvester Brooke E, Chang Matthew T, Elzein Arijh, Gao Jianjiong, Han Weiwei, Liu Ye, Xu Dong, Gao Sizhi P, Gorelick Alexander N, Jones Alexis M, Kiliti Amber J, Nissan Moriah H, Nimura Clare A, Poteshman Abigail N, Yao Zhan, Gao Yijun, Hu Wenhuo, Wise Hannah C, Gavrila Elena I, Shoushtari Alexander N, Tiwari Shakuntala, Viale Agnes, Abdel-Wahab Omar, Merghoub Taha, Berger Michael F, Rosen Neal, Taylor Barry S, Solit David B
Abstract excerpt
Despite significant advances in cancer precision medicine, a significant hurdle to its broader adoption remains the multitude of variants of unknown significance identified by clinical tumor sequencing and the lack of biologically validated methods to distinguish between functional and benign variants. Here we used functional data on MAP2K1 and MAP2K2 mutations generated in real-time within a co-clinical trial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.